Dan’s the man…at Custom Biologics

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dan Mamelak, Founder & President at Custom Biologics.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dan, covering:

• How reading The Billion-dollar Molecule inspired him to explore a pathway into cutting-edge drug development
• The founding story of his company and some timeless advice not to burn bridges
• How the Canadian conveyor belt of intelligent, talented young science graduates has helped fuel the company’s growth
• Why being privately owned has contributed to the company’s unique culture

Dan is responsible for the company’s strategic direction. From the outset of his career, Dan recognized the need for solid bioanalytical expertise to support the drug discovery programs of both developing and established biopharmaceutical companies.

In 2004, Dan established Custom Biologics, a large-molecule bioanalytical CRO that designs and validates assays to measure the potency of biotherapeutic drugs, including therapeutic monoclonal antibodies and genetic therapies. Recently, the Genomics division of Custom Biologics has developed novel isothermal nucleic acid molecular diagnostic tests to rapidly identify human and food-borne pathogens.

Before founding Custom Biologics, Dan was a Senior Scientist at Affinium Pharmaceuticals, an established company that accelerates the development of small molecules into new medicines. Dan holds a Ph.D. in Biochemistry from the University of Toronto.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.